Division of H. Lundbeck AS
Latest From Lundbeck Inc.
Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.
Dainippon drug likely to become first atypical to be approved for adolescent schizophrenia in Japan following planned filing based on positive new Phase III results.
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Ovation Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- H. Lundbeck AS
- Senior Management
- Doug Carlson, Sr. Dir., Corp. BD & Strategy
- Contact Info
Phone: (800) 455-1141
4 Parkway N.
Deerfield, IL 60015
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.